S100B and schizophrenia: In contrast to antidepressant drugs, where S100B serum levels have been discussed as indicators/biomarkers for successful treatment (Schroeter et al., 2008), as of yet there is no meta-analytic evidence for serum S100B being related to treatment success of neuroleptics/antipsychotics in schizophrenia.